semaglutide for kidney disease Ozempic picks up FDA indication to treat chronic FDA approves Ozempic to reduce

Kido Y, Tamai I, Ohnari A, Sai Y, Kagami T, Nezu J, et al

How soon can I expect to see results with Everyday+

Potential candidates for off-label use: Clinicians may consider GLP-1 therapy for women with PCOS who meet the following criteria: Overweight or obesity (particularly BMI 30 kg/m) with PCOS Insulin resistance or impaired glucose tolerance Inadequate response to lifestyle modification and other treatments No contraindications to GLP-1 therapy Not planning pregnancy in the immediate future Contraindications and precautions: GLP-1 receptor agonists are contraindicated in pregnancy and breastfeeding

Similar exposure is achieved with subcutaneous administration of semaglutide in the abdomen, thigh, or upper arm

But its an interesting side benefit for those exploring peptide stacks that target both growth and appearance